Cargando…
Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects
Lung cancer, the second most commonly diagnosed cancer, is the major cause of fatalities worldwide for both men and women, with an estimated 2.2 million new incidences and 1.8 million deaths, according to GLOBOCAN 2020. Although various risk factors for lung cancer pathogenesis have been reported, c...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145966/ https://www.ncbi.nlm.nih.gov/pubmed/35631448 http://dx.doi.org/10.3390/ph15050624 |
_version_ | 1784716444714401792 |
---|---|
author | Gangwar, Shailendra Kumar Kumar, Aviral Yap, Kenneth Chun-Hong Jose, Sandra Parama, Dey Sethi, Gautam Kumar, Alan Prem Kunnumakkara, Ajaikumar B. |
author_facet | Gangwar, Shailendra Kumar Kumar, Aviral Yap, Kenneth Chun-Hong Jose, Sandra Parama, Dey Sethi, Gautam Kumar, Alan Prem Kunnumakkara, Ajaikumar B. |
author_sort | Gangwar, Shailendra Kumar |
collection | PubMed |
description | Lung cancer, the second most commonly diagnosed cancer, is the major cause of fatalities worldwide for both men and women, with an estimated 2.2 million new incidences and 1.8 million deaths, according to GLOBOCAN 2020. Although various risk factors for lung cancer pathogenesis have been reported, controlling smoking alone has a significant value as a preventive measure. In spite of decades of extensive research, mechanistic cues and targets need to be profoundly explored to develop potential diagnostics, treatments, and reliable therapies for this disease. Nuclear receptors (NRs) function as transcription factors that control diverse biological processes such as cell growth, differentiation, development, and metabolism. The aberrant expression of NRs has been involved in a variety of disorders, including cancer. Deregulation of distinct NRs in lung cancer has been associated with numerous events, including mutations, epigenetic modifications, and different signaling cascades. Substantial efforts have been made to develop several small molecules as agonists or antagonists directed to target specific NRs for inhibiting tumor cell growth, migration, and invasion and inducing apoptosis in lung cancer, which makes NRs promising candidates for reliable lung cancer therapeutics. The current work focuses on the importance of various NRs in the development and progression of lung cancer and highlights the different small molecules (e.g., agonist or antagonist) that influence NR expression, with the goal of establishing them as viable therapeutics to combat lung cancer. |
format | Online Article Text |
id | pubmed-9145966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91459662022-05-29 Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects Gangwar, Shailendra Kumar Kumar, Aviral Yap, Kenneth Chun-Hong Jose, Sandra Parama, Dey Sethi, Gautam Kumar, Alan Prem Kunnumakkara, Ajaikumar B. Pharmaceuticals (Basel) Review Lung cancer, the second most commonly diagnosed cancer, is the major cause of fatalities worldwide for both men and women, with an estimated 2.2 million new incidences and 1.8 million deaths, according to GLOBOCAN 2020. Although various risk factors for lung cancer pathogenesis have been reported, controlling smoking alone has a significant value as a preventive measure. In spite of decades of extensive research, mechanistic cues and targets need to be profoundly explored to develop potential diagnostics, treatments, and reliable therapies for this disease. Nuclear receptors (NRs) function as transcription factors that control diverse biological processes such as cell growth, differentiation, development, and metabolism. The aberrant expression of NRs has been involved in a variety of disorders, including cancer. Deregulation of distinct NRs in lung cancer has been associated with numerous events, including mutations, epigenetic modifications, and different signaling cascades. Substantial efforts have been made to develop several small molecules as agonists or antagonists directed to target specific NRs for inhibiting tumor cell growth, migration, and invasion and inducing apoptosis in lung cancer, which makes NRs promising candidates for reliable lung cancer therapeutics. The current work focuses on the importance of various NRs in the development and progression of lung cancer and highlights the different small molecules (e.g., agonist or antagonist) that influence NR expression, with the goal of establishing them as viable therapeutics to combat lung cancer. MDPI 2022-05-18 /pmc/articles/PMC9145966/ /pubmed/35631448 http://dx.doi.org/10.3390/ph15050624 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Gangwar, Shailendra Kumar Kumar, Aviral Yap, Kenneth Chun-Hong Jose, Sandra Parama, Dey Sethi, Gautam Kumar, Alan Prem Kunnumakkara, Ajaikumar B. Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects |
title | Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects |
title_full | Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects |
title_fullStr | Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects |
title_full_unstemmed | Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects |
title_short | Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects |
title_sort | targeting nuclear receptors in lung cancer—novel therapeutic prospects |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145966/ https://www.ncbi.nlm.nih.gov/pubmed/35631448 http://dx.doi.org/10.3390/ph15050624 |
work_keys_str_mv | AT gangwarshailendrakumar targetingnuclearreceptorsinlungcancernoveltherapeuticprospects AT kumaraviral targetingnuclearreceptorsinlungcancernoveltherapeuticprospects AT yapkennethchunhong targetingnuclearreceptorsinlungcancernoveltherapeuticprospects AT josesandra targetingnuclearreceptorsinlungcancernoveltherapeuticprospects AT paramadey targetingnuclearreceptorsinlungcancernoveltherapeuticprospects AT sethigautam targetingnuclearreceptorsinlungcancernoveltherapeuticprospects AT kumaralanprem targetingnuclearreceptorsinlungcancernoveltherapeuticprospects AT kunnumakkaraajaikumarb targetingnuclearreceptorsinlungcancernoveltherapeuticprospects |